Gynecologic Cancer Services
The UAB Division of Gynecologic Oncology is a multidisciplinary team of specialty physicians, nurses, and consultants providing comprehensive, compassionate care in treating women’s cancers. Each year, UAB treats more than 2,500 women battling cancer diagnoses.
As part of the UAB Comprehensive Cancer Center, the Division of Gynecologic Oncology assists women with the physical and emotional challenges associated with gynecologic cancer. Our experts design customized treatment plans for each patient’s individual needs and use the latest technology to screen for and treat all types of women’s reproductive cancers. Our research team is dedicated to improving treatments and ultimately finding a cure for these cancers.
UAB Medicine developed a special program to treat gynecological carcinosarcoma (GCS), also known as MMMT (malignant mixed Müllerian tumor), which is a rare and aggressive cancer found primarily in the ovaries and uterus. It usually occurs in post-menopausal women. As part of this GCS Project, UAB is involved in several research efforts and clinical trials designed to better understand GCS and improve the survival rate for patients.
The O'Neal Comprehensive Cancer Center at UAB provides the latest in advanced cancer care for patients in Alabama and the surrounding region. Cancer specialists at UAB Medicine employ a team approach, combining multiple specialists trained in medical, surgical, and radiation oncology as well as pathology and other key fields. Our National Cancer Institute-designated Comprehensive Cancer Center is the only one in a six-state region and one of just 40 in the nation. Our 330-plus physicians and researchers treat an estimated 5,000 new patients each year, and they are dedicated to providing leading-edge care in a compassionate environment while developing a comprehensive treatment plan designed specifically for each patient.
Our excellence has not gone unnoticed. Becker's Hospital Review included UAB on its recent list of "100 Hospitals and Health Systems with Great Oncology Programs” – a testament to patient care, cancer outcomes, and research – and the center has consistently been recognized for excellence by U.S. News & World Report. Additionally, the center developed the UAB Health System Cancer Community Network, an elite group that includes 10 partner hospitals across five states, with the goal of expanding the availability and quality of cancer services for patients. Together with our team of experts, your fight is our fight.
IMAGES AND VIDEOS
Robot-Assisted Hysterectomy at UAB Medicine
UAB is an active participant in research and clinical trials. We encourage you to speak to your physician about research and clinical trial options and browse the link below for more information.View Clinical Trials
UAB Hospital first in Alabama to offer first-of-its-kind dissolving heart stent
The interventional cardiology team at UAB Hospital recently added to its longstanding reputation as a pioneer in the development and implementation of stents by becoming the first in Alabama to offer patients with coronary artery disease a new treatment option that disappears over time.
On July 20, Massoud Leesar, M.D., a professor in UAB’s Division of Cardiovascular Disease, implanted a patient with the world’s first FDA-approved dissolving heart stent for the first time in Alabama. The Absorb bioresorbable vascular coronary stent is a major advance in the treatment of coronary heart disease, which is responsible for about 370,000 deaths each year in the United States, according to the National Heart, Lung, and Blood Institute. This type of stent has been in the making for nearly 15 years.
While stents are traditionally made of metal, the Absorb stent is made of a naturally dissolving material called polylactide, similar to dissolving stitches or sutures.
“Since the Absorb stent gradually dissolves, this may be a safer long-term option for patients because metal stents can clot and occlude the artery,” Leesar said.
The stent is placed into the artery on a balloon at the end of a thin flexible tube, much like the procedure used to place bare metal and drug eluting coronary stents. It is then expanded by inflating the balloon that pushes the plaque against the artery wall to enable greater blood flow. The balloon is removed, leaving the Absorb stent to slowly release medication to the diseased area. With blood flow restored, the stent begins dissolving.
After Absorb dissolves, it allows the artery to pulse and flex naturally. It may also reduce the risk of future blockages that occur with metallic stents, and makes it easier for doctors to offer additional interventions in the future if necessary. During the dissolving period, Absorb metabolizes into water and carbon dioxide, two elements that occur naturally in the body. All that remain in the artery are two pairs of tiny metallic markers that enable a physician to see where the device was placed. After three years, the device is completely dissolved and the vessel can remain open and pulsate on its own.
Calvin Burnett of Albertville, Alabama, is the first patient in the state to receive the new Absorb stent. After Burnett was diagnosed with rectal cancer in September 2015, his oncologist recommended he see a cardiologist at UAB following complaints of tightness in his chest.
“I’ve always been kind of physically active, so this kind of threw me for a loop,” Burnett said.
Two days after his stress test, an Absorb stent was placed. Burnett says he is grateful that medicine has come so far.
“I think this is such a great thing,” he said. “I’m looking forward to getting back to riding horses.”
Burnett says he could not imagine having his procedure done anywhere other than at UAB.
To ensure optimal patient selection and implant technique, UAB’s interventional cardiology team underwent extensive training on the new device.
“One of the advantages of this new stent is that the risk of a metal stent’s suddenly clotting is a major issue long-term,” Leesar said. “Since the new stent dissolves over time, this risk can be eliminated, and the vessel has the potential to be open more than to before with the stent.”
Currently, patients who receive the new dissolving stent will have to meet certain criteria. Leesar suggests patients talk with their cardiologists to see if they meet those criteria, and to learn more about the Absorb stent and its capabilities.
Source: UAB News